From: New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications
Clinical Outcomes | miRNAs | Sample type | Detection time | Therapy | Cancer | Patient cohorta | Ref |
---|---|---|---|---|---|---|---|
Better outcomes | miR-378 | tissue | post-therapy | bevacizumab | ovarian cancer | 113/34 | [104] |
miR-455-5p | tissue | post-therapy | bevacizumab | mCRC | 212/121 | [105] | |
miR-221 | tissue | post-therapy | sunitinib | mRCC | 30/27 | [107] | |
miR-155, miR-484 | tissue | post-therapy | sunitinib | mRCC | 16/63 | [108] | |
miR-126 | blood | pre- and post-therapy | bevacizumab | mCRC | 75/68 | [111] | |
miR-665 | blood | pre-therapy | bevacizumab/erlotinib | NSCLC | 51/50 | [112] | |
Worse outcomes | miR-664-3p, | tissue | post-therapy | bevacizumab | mCRC | 212/121 | [105] |
miR-425-3p | tissue | pre- and post-therapy | sorafenib | HCC | 26/58 | [106] | |
miR-223 | blood | pre-therapy | bevacizumab/erlotinib | NSCLC | 51/50 | [112] |